RealFeedApp beta
- Two of three glaucoma patients showed early visual-field signals
The Phase 1 trial of ER-100, which activates Yamanaka factors in the eye, did not cause serious adverse events in three participants. Early visual field signals were observed in two of the three patients with open-angle glaucoma.
- Field
- ageing and longevity
- What they did
- Researchers conducted the first phase of clinical trials for the ER-100 therapy in humans, which includes three Yamanaka factors to restore retinal cell function in patients with glaucoma. Over 56 days, two out of three participants showed early signs of improved visual field without serious side effects.
- Why it matters
- The data support escalating the drug dose, marking a potential first step toward applying partial cell reprogramming methods to extend human life and restore functions.
#partial reprogramming#er-100#glaucoma#yamanaka factors#clinical trial
